



La filiera salute nella prossima programmazione europea di Horizon 2020

Sfide e opportunità internazionali nel
settore della salute
Milano, 29 maggio 2017
Brussels (video-conferenza)



Rosanna D'Amario
Senior Expert, Strategy Unit
Health Directorate
DG Research & Innovation
European Commission
Brussels, Belgium

Argomenti principali

- Introduzione a Horizon 2020 e Sfida sociale 'Salute, cambiamento demografico e benessere' (SC1)
- Innovative Medicines Initiative (IMI)
- Cooperazione internazionale
- Verso FP9



H2020 and Societal challenge 'Health, demographic change and well-being' (SC1)

3 Os of Commissioner Moedas



"As I see it, European success now lies in sharing as soon as possible, (...). The days of open science have arrived."

Speech at "Presidency Conference Open Science", 04 of April, 2016, Amsterdam



Carlos Moedas
**EU Commissioner for Research,
Science and Innovation**

Horizon 2020 pillars

- **European Research Council**
- **Future and Emerging Technologies**
- **Marie Skłodowska Curie Actions**
- **Research Infrastructures**

1- Excellent science

7 societal challenges, of which SC1 'Health, demographic change and wellbeing'

- **Leadership in enabling and industrial technologies**
- **Access to risk finance**
- **Innovation in SMEs**

2- Industrial leadership

3- Societal challenges

EU health research



Collaborative research

Real-life solutions based
on joint problem-solving



Public-private partnerships

Investing together for
next generation medicines
and treatments



Global co-operation

One world, one team
working to solve
common health challenges



Public partnerships

Harnessing global
expertise to fight
poverty-related diseases

Our priorities



Call 2014-15:
EUR 1.3 B

Call 2016-17:
EUR 1.4 B

Personalised medicine



Healthy ageing
(2014-2017)



Health ICT
(2014-2017)



Infectious Diseases
(2014-2017)

Human
biomonitoring
(2016-2017)





Research and
Innovation





Maternal and child
health
(2016-2017)

Organisations participating in SC1


Participations per organisation type



EC Contribution per organisation type




EU-28 by participation and EC contribution





European
Commission

EC contribution in EU-28



Workprogramme 2018-20


Main policy objectives

- To improve health and well-being outcomes
- To promote active and healthy ageing
- To promote a more competitive European health industry and care sector
- To maximise the digital potential
- To promote the EU as a global leader in the health area

Priorities in 2018-2020

1. **Better Health and care, economic growth and sustainable health systems**
 - Personalised medicine
 - Innovative health and care industry
 - Infectious diseases and improving global health
 - Innovative health and care systems - Integration of care
 - Decoding the role of the environment for health and well-being
2. **Digital transformation in Health and Care**
3. **Trusted digital solutions and Cybersecurity in Health and Care**

SC1 work programme budgets



Sources: 2014 and 2015 – Committed funds
 2016 – 2017 - Published Work Programme
 2018 to 2020 – *Provisional Budgets*

Timetable for WP 2018-20

- ❖ 2016: Advisory Group produced a report, which was made public for consultation
- ❖ End 2016: EC published 'scoping papers', consulted with Programme Committee
- ❖ 2017: Consultation with Programme Committee; internal consultation; publication around November 2017
- ❖ 2018: Update for 2019
- ❖ 2019: Update and financing decision for 2020



Innovative Medicines Initiative 2 (IMI2)


IMI – Europe's partnership for health

IMI1: 2008-2013

€ 2 billion budget
59 projects


IMI2: 2014-2020

€3.3 billion budget
More ambitious
More open
Greater scope




IMI2 Strategic agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines






An international, cross-sector community



- ***Over 9 000 researchers working for:***
 - open collaboration
 - improved R&D productivity
 - innovative approaches to unmet medical needs

Figures from June 2016

Distribution of funding – IMI1



EFPIA contributions



IMI contributions



International cooperation in Societal challenge 1

Horizon 2020: open to the world

General opening


Horizon 2020 is fully open to participation of entities from across the globe



Targeted opening

Many topics are flagged as specifically relevant for international cooperation, identifying upfront the targeted area and partner country or region


International cooperation increases quality



Average Relative Citations (ARC) of publications by type of co-operation, 2010

International participation increases H2020 success rate

Success Rates for different numbers
of Non-Associated Third Country applicants




Note: Data for collaborative projects of Horizon 2020. Success rate is the ratio of mainlisted over eligible proposals.

Source: DG RTD - International Cooperation

Data: CORDA, extraction date: 28/09/2016

Participation of Third countries in SC1: collaborative projects





Open to the world

Multi-lateral health research activities



HUMAN FRONTIER SCIENCE PROGRAM
FUNDING FRONTIER RESEARCH INTO COMPLEX BIOLOGICAL SYSTEMS
Supported by

www.hfsp.org


Research and
Innovation



Towards FP9: Process, Key Questions



Towards FP9: learning from the past & benefitting of co-design





10 Key messages from the stakeholder consultation

High satisfaction with the programme.



Increased budget is needed and programme oversubscription is an urgent issue.



Fosters **excellence** and should continue to be excellence based.



Should better address citizens' needs.



Should further support market-creating innovation but at the same time there should be balance between research and innovation.



10 Key messages from the stakeholder consultation

Simplified, cost of participation is lower than in previous programmes but further simplification is needed.



Combined research and innovation programme better addresses stakeholder needs. But funding landscape remains **complex** to understand and needs to be rationalised.



Collaborative projects are the key and most relevant feature of the programme.



Some aspects of the **evaluation process** could be further improved.



Brings **EU Added Value** through unique opportunities to collaborate, access new knowledge and know-how and financing of projects which otherwise would not be supported.



Some key questions for shaping FP9

Excellence vs. cohesion

Continuity vs. breaking with the past

Top-down vs. bottom-up

Output-based vs. cost-based

Grants vs. loans

International vs. European only

Incremental vs. disruptive

Single beneficiaries vs. collaborative

All businesses eligible vs. focus predominantly on SMEs

Include defence vs. only civil / dual research

Maggiori informazioni @

➤ Participant portal

- ✓ <http://ec.europa.eu/research/participants/portal/desktop/en/home.html>

➤ Societal challenge 1

- ✓ <http://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-demographic-change-and-wellbeing>

➤ Research & Innovation – shaping our future: 7.07.2017

- ✓ <http://ec.europa.eu/research/index.cfm?pg=events&eventcode=032132EF-D4BD-39B3-6C981F6EB7F3D7C4>

✓ FACEBOOK:

- ✓ <https://www.facebook.com/EUScienceInnov/>
- ✓ <https://www.facebook.com/cmoedas/>

E grazie dell'attenzione!